Recombinant Anti-B cell lymphoma BCL1 Idiotype x Anti-CD64 Bispecific Antibody (Fab-IgG) (FABIG-001)

Recombinant Anti-B cell lymphoma BCL1 Idiotype x Anti-CD64 Bispecific Antibody (Fab-IgG) is designed to be expressed as three chains, assembling in vivo and resulting in the construct of Fab-IgG (Tandem Fab-Fc). Fab-IgG has standard Fab and Fc domains, with no mutations, which may permit it has similar affinity binding and PK profile comparable to the parental antibodies. This BsAb can retarget immune cells to tumor cells. It is designed for the research of B cell lymphoma therapy.

Datasheet INQUIRY

Specifications

Targets

B cell lymphoma BCL1 Idiotype & CD64

Type

Fab-IgG

Species Reactivity

Mouse

Application

FuncS; Promising therapeutic agent

Related Disease

B cell lymphoma

Targets

Target 1

B cell lymphoma BCL1 Idiotype

Alternative Names

B cell lymphoma BCL1 Idiotype; B cell lymphoma; BCL1; Idiotype; Id; 31D1; 32D1

Target 2

CD64

Gene ID

14129

UniProt ID

P26151

Alternative Names

FcγRI; FCGR1A; Fc fragment of IgG, high affinity Ia, receptor (CD64); CD64; FCRI; CD64A; IGFR1; high affinity immunoglobulin gamma Fc receptor I; fcgammaRIa; Fc-gamma RI; fc-gamma RIA; Fc gamma receptor; IgG Fc receptor I; Fc-gamma receptor I A1; Fc fragment of IgG, high affinity Ia, receptor for (CD64); FCGR1B, FCGR1C

Our products and services are for research use only, and not for use in diagnostic or therapeutic procedures.

Online Inquiry

Related products of "B cell lymphoma BCL1 Idiotype & CD64"

See other bsAb targets related to "B cell lymphoma BCL1 Idiotype"

See other bsAb targets related to "CD64"

Customer Reviews and Q&As

There are currently no customer reviews or questions for Recombinant Anti-B cell lymphoma BCL1 Idiotype x Anti-CD64 Bispecific Antibody (Fab-IgG) (FABIG-001). Click the button below to contact us or submit your feedback about this product.

Recombinant Anti-B cell lymphoma BCL1 Idiotype x Anti-CD64 Bispecific Antibody (Fab-IgG) (CAT#: FABIG-001)

Specifications

Targets

Customer Reviews and Q&As